The Department of Justice has issued Merck & Co a subpoena seeking information about the drugmaker's marketing of three drugs acquired in its 2009 merger with Schering-Plough Corp.

The subpoena, which Merck disclosed in its quarterly securities filing, involves the brain cancer drug Temodar, hepatitis C medicine Peg-Intron, and Intron A, which is approved for hepatitis C as well as for forms of cancer.

The subpoena seeks information from January 2004 to the present in a federal health care investigation under criminal statutes, Merck said in its filing. The company said it is cooperating with the probe.

(Reporting by Lewis Krauskopf, editing by Gerald E. McCormick)

Merck & Co. Marketing